US FDA approves Dupixent to treat younger kids with esophageal condition

FDAReuters

US FDA approves Dupixent to treat younger kids with esophageal condition

Jan 25 (Reuters) – The U.S. health regulator has approved the use of Regeneron and Sanofi’s Dupixent to treat an allergic inflammation of the esophagus in children aged one to 11 years old and weighing at least 15 kg, the companies said on Thursday.
 
The U.S. Food and Drug Administration (FDA) in 2022 approved the blockbuster anti-inflammatory drug for treating eosinophilic esophagitis (EoE) in patients aged 12 years and older, making it the first for the immune condition in the country.

In EoE, white blood cells called eosinophils build up in the esophagus, resulting in damage and inflammation that can impact the ability to eat food.

About 21,000 children below 12 years are being treated for EoE in the U.S. and around 9,000 of those do not respond satisfactorily to unapproved therapies, Sanofi said in September.

Dupixent’s list price is $3,803.20 per carton for all EoE patients, a Sanofi spokesperson said, adding, most people will not pay the list price.

 

/by
You might also like
MerckUS FDA approves Merck’s therapy for rare lung condition
AbbottAbbott receives FDA clearance for whole blood rapid test to help with assessment of concussion at the patient’s bedside
Neurofilament as a surrogate endpoint goes on trial in Tofersen adcomm
FDAReutersUS FDA allows import of syphilis drug to address shortages
SanofiSanofi bolsters diabetes position with $2.9B Provention buyout
FDAFDA clears first OTC continuous glucose monitor
FDAMesoblast shares tank after US FDA rejects cell therapy for children
PfizerU.S. FDA approves Pfizer’s nasal spray for migraine